83.58
前日終値:
$87.29
開ける:
$83.175
24時間の取引高:
5.59M
Relative Volume:
1.45
時価総額:
$33.26B
収益:
$4.15B
当期純損益:
$535.20M
株価収益率:
62.37
EPS:
1.34
ネットキャッシュフロー:
$575.20M
1週間 パフォーマンス:
-4.56%
1か月 パフォーマンス:
-2.59%
6か月 パフォーマンス:
+7.47%
1年 パフォーマンス:
-25.49%
Dexcom Inc Stock (DXCM) Company Profile
DXCM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
DXCM
Dexcom Inc
|
83.58 | 33.26B | 4.15B | 535.20M | 575.20M | 1.34 |
![]()
ABT
Abbott Laboratories
|
136.26 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
104.78 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
396.74 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
88.75 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
77.18 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-16 | 開始されました | Truist | Buy |
2025-05-30 | 開始されました | Goldman | Buy |
2025-04-10 | 開始されました | Mizuho | Outperform |
2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
2023-03-29 | 開始されました | UBS | Buy |
2023-01-26 | 開始されました | Wolfe Research | Outperform |
2022-10-18 | 開始されました | Barclays | Equal Weight |
2022-10-12 | 開始されました | Jefferies | Buy |
2022-07-15 | 開始されました | Bernstein | Outperform |
2022-03-02 | 再開されました | BofA Securities | Buy |
2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
2021-07-21 | 再開されました | Cowen | Outperform |
2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-15 | 開始されました | Atlantic Equities | Overweight |
2021-01-06 | アップグレード | UBS | Neutral → Buy |
2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
2020-03-05 | 開始されました | Citigroup | Buy |
2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
2019-10-23 | 開始されました | Stifel | Buy |
2018-11-28 | 開始されました | UBS | Neutral |
2018-10-19 | アップグレード | Goldman | Sell → Neutral |
2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
2018-05-11 | 開始されました | BofA/Merrill | Buy |
2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
2018-04-04 | 開始されました | Goldman | Sell |
2018-04-04 | 開始されました | Guggenheim | Neutral |
2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
Dexcom EVP Brown sells $41k in shares - Investing.com
Diabetics at Risk: FDA Issues Highest-Level Recall on 2M Dexcom Devices Over 'Deadly Fault' - inkl
Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight - GlobeNewswire Inc.
Dexcom Ireland announce golfer Liam Nolan as a brand ambassador - Galway Advertiser
Dexcom recalls more than 2 million CGM receivers for lack of audible alarm - MedTech Dive
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025 - Dexcom
Breakthrough Study Reveals Doctors Choose CGM Over Medications as Future of Type 2 Diabetes Treatment - Stock Titan
Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks - FinancialContent
Dexcom Faces TM Suit Over 'Stelo' Glucose Monitor Product - Law360
Goldman Sachs Initiates Coverage of DexCom (DXCM) With Buy Rating - MSN
DexCom’s SWOT analysis: CGM leader’s stock poised for growth amid challenges - Investing.com
DexCom's SWOT analysis: CGM leader's stock poised for growth amid challenges - Investing.com
Expert Outlook: DexCom Through The Eyes Of 8 Analysts - Nasdaq
DexCom Stock: Is DXCM Underperforming the Health Care Sector? - MSN
DexCom (DXCM) Receives 'Buy' Rating from Truist Securities with $102 Price Target | DXCM Stock News - GuruFocus
DexCom (DXCM) Gains Analysts' Favor Despite Past Challenges - GuruFocus
DexCom Stock: Is DXCM Underperforming The Health Care Sector? - Barchart.com
DexCom (DXCM) Receives Buy Rating Amid Promising Market Prospects | DXCM Stock News - GuruFocus
Truist Initiates DexCom at Buy With $102 Price Target - MarketScreener
DexCom Insiders Sell US$11m Of Stock, Possibly Signalling Caution - simplywall.st
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - Business Wire
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7 - MassDevice
Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users - marketscreener.com
Insulet Releases Omnipod 5 App for iPhone with Dexcom G7 CGM in U.S. - Medical Product Outsourcing
Diabetes partnerships abound ahead of ADA - BioWorld MedTech
Insulet's Omnipod® 5 App For iPhone With Dexcom G7 Integration Now Available To All US Users - MarketScreener
Insulet (PODD) Omnipod 5 App Now Compatible with Dexcom G7 on iPhone | PODD Stock News - GuruFocus
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users | PODD Stock News - GuruFocus
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users - Business Wire
DexCom, Inc. (DXCM) Stock Analysis: Analyst Consensus Points to 13.59% Potential Upside - DirectorsTalk Interviews
DexCom (NASDAQ:DXCM) Stock Rating Upgraded by Wall Street Zen - Defense World
DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
BGM and CGM Market is Set to Experience a Revolutionary Growth | Abbott Laboratories , Dexcom, Medtronic PLC - openPR.com
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Should You Be Excited About DexCom, Inc.'s (NASDAQ:DXCM) 24% Return On Equity? - simplywall.st
Goldman Sachs Initiates Coverage of DexCom (XTRA:DC4) with Buy Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of DexCom (BIT:1DXCM) with Buy Recommendation - Nasdaq
DexCom (NASDAQ:DXCM) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation - Nasdaq
Forecasting The Future: 7 Analyst Projections For DexCom - Benzinga
DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Call Transcript - MSN
Jefferies Adjusts Price Target on DexCom to $110 From $105, Maintains Buy Rating - marketscreener.com
Goldman Sachs Initiates DexCom at Buy With $104 Price Target - marketscreener.com
DexCom (DXCM) Receives Positive Coverage with Growth Potential | - GuruFocus
DexCom (DXCM) Receives Positive Coverage with Growth Potential | DXCM Stock News - GuruFocus
Dexcom’s EVP Sadie Stern sells $526,318 in shares - Investing.com
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - The Globe and Mail
DexCom, Inc. (DXCM) Stock Analysis: 15.97% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews
DexCom’s SWOT analysis: CGM leader faces supply challenges amid growth - Investing.com
DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move? - Smartkarma
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
Dexcom Inc (DXCM) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
FOLETTA MARK G | Director |
Jun 16 '25 |
Sale |
83.13 |
2,750 |
228,605 |
56,621 |
Brown Michael Jon | EVP, Chief Legal Officer |
Jun 16 '25 |
Sale |
82.80 |
500 |
41,400 |
95,102 |
AUGUSTINOS NICHOLAS | Director |
Jun 16 '25 |
Sale |
82.80 |
3,672 |
304,042 |
33,411 |
AUGUSTINOS NICHOLAS | Director |
Jun 13 '25 |
Sale |
81.69 |
2,618 |
213,864 |
37,083 |
大文字化:
|
ボリューム (24 時間):